These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 38517752)

  • 1. Structural mechanisms for VMAT2 inhibition by tetrabenazine.
    Dalton MP; Cheng MH; Bahar I; Coleman JA
    Elife; 2024 Mar; 12():. PubMed ID: 38517752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural mechanisms for VMAT2 inhibition by tetrabenazine.
    Dalton MP; Cheng MH; Bahar I; Coleman JA
    bioRxiv; 2024 Feb; ():. PubMed ID: 37732203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transport and inhibition mechanisms of human VMAT2.
    Wu D; Chen Q; Yu Z; Huang B; Zhao J; Wang Y; Su J; Zhou F; Yan R; Li N; Zhao Y; Jiang D
    Nature; 2024 Feb; 626(7998):427-434. PubMed ID: 38081299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of conformationally sensitive residues essential for inhibition of vesicular monoamine transport by the noncompetitive inhibitor tetrabenazine.
    Ugolev Y; Segal T; Yaffe D; Gros Y; Schuldiner S
    J Biol Chem; 2013 Nov; 288(45):32160-32171. PubMed ID: 24062308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transport and inhibition mechanism for VMAT2-mediated synaptic vesicle loading of monoamines.
    Wang Y; Zhang P; Chao Y; Zhu Z; Yang C; Zhou Z; Li Y; Long Y; Liu Y; Li D; Wang S; Qu Q
    Cell Res; 2024 Jan; 34(1):47-57. PubMed ID: 38163846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurotransmitter recognition by human vesicular monoamine transporter 2.
    Im D; Jormakka M; Juge N; Kishikawa JI; Kato T; Sugita Y; Noda T; Uemura T; Shiimura Y; Miyaji T; Asada H; Iwata S
    Nat Commun; 2024 Sep; 15(1):7661. PubMed ID: 39284862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of neurotransmitter transport and drug inhibition in human VMAT2.
    Pidathala S; Liao S; Dai Y; Li X; Long C; Chang CL; Zhang Z; Lee CH
    Nature; 2023 Nov; 623(7989):1086-1092. PubMed ID: 37914936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emulating proton-induced conformational changes in the vesicular monoamine transporter VMAT2 by mutagenesis.
    Yaffe D; Vergara-Jaque A; Forrest LR; Schuldiner S
    Proc Natl Acad Sci U S A; 2016 Nov; 113(47):E7390-E7398. PubMed ID: 27821772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A fluorescent-based assay for live cell, spatially resolved assessment of vesicular monoamine transporter 2-mediated neurotransmitter transport.
    Bernstein AI; Stout KA; Miller GW
    J Neurosci Methods; 2012 Aug; 209(2):357-66. PubMed ID: 22698664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation and evaluation of tetrabenazine enantiomers and all eight stereoisomers of dihydrotetrabenazine as VMAT2 inhibitors.
    Yao Z; Wei X; Wu X; Katz JL; Kopajtic T; Greig NH; Sun H
    Eur J Med Chem; 2011 May; 46(5):1841-8. PubMed ID: 21396745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VMAT2 inhibitors for the treatment of hyperkinetic movement disorders.
    Koch J; Shi WX; Dashtipour K
    Pharmacol Ther; 2020 Aug; 212():107580. PubMed ID: 32454050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tetrabenazine inhibition of monoamine uptake and methamphetamine behavioral effects: locomotor activity, drug discrimination and self-administration.
    Meyer AC; Horton DB; Neugebauer NM; Wooters TE; Nickell JR; Dwoskin LP; Bardo MT
    Neuropharmacology; 2011 Sep; 61(4):849-56. PubMed ID: 21669212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individual residues contribute to multiple differences in ligand recognition between vesicular monoamine transporters 1 and 2.
    Finn JP; Edwards RH
    J Biol Chem; 1997 Jun; 272(26):16301-7. PubMed ID: 9195934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deutetrabenazine for the treatment of Huntington's chorea.
    Bashir H; Jankovic J
    Expert Rev Neurother; 2018 Aug; 18(8):625-631. PubMed ID: 29996061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pyrrolidine analogues of lobelane: relationship of affinity for the dihydrotetrabenazine binding site with function of the vesicular monoamine transporter 2 (VMAT2).
    Vartak AP; Nickell JR; Chagkutip J; Dwoskin LP; Crooks PA
    J Med Chem; 2009 Dec; 52(23):7878-82. PubMed ID: 19691331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry.
    Wimalasena K
    Med Res Rev; 2011 Jul; 31(4):483-519. PubMed ID: 20135628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters.
    Goswami R; Ponde DE; Kung MP; Hou C; Kilbourn MR; Kung HF
    Nucl Med Biol; 2006 Aug; 33(6):685-94. PubMed ID: 16934687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-terminus regulation of VMAT2 mediates methamphetamine-stimulated efflux.
    Torres B; Ruoho AE
    Neuroscience; 2014 Feb; 259():194-202. PubMed ID: 24321511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vesicular monoamine transporter 2: role as a novel target for drug development.
    Zheng G; Dwoskin LP; Crooks PA
    AAPS J; 2006 Nov; 8(4):E682-92. PubMed ID: 17233532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of VMAT2 by β2-adrenergic agonists, antagonists, and the atypical antipsychotic ziprasidone.
    Støve SI; Skjevik ÅA; Teigen K; Martinez A
    Commun Biol; 2022 Nov; 5(1):1283. PubMed ID: 36418492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.